Skip Navigation

European Journal of Heart Failure 2004 6(2):161-172; doi:10.1016/j.ejheart.2003.11.004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Torrado, M.
Right arrow Articles by Mikhailov, A. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Torrado, M.
Right arrow Articles by Mikhailov, A. T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 European Society of Cardiology

Left–right asymmetric ventricular expression of CARP in the piglet heart: regional response to experimental heart failure{star}

Mario Torradoa, Eduardo Lópezb, Alberto Centenob, Alfonso Castro-Beirasb and Alexander T. Mikhailova,*

a Developmental Biology Unit, Institute of Health Sciences University of La Coruña, Campus de Oza, Building ‘El Fortín’, Las Xubias s/n, La Coruña 15006, Spain
b University Hospital ‘Juan Canalejo’ Las Xubias de arriba 58, La Coruña 15006, Spain

* Corresponding author. Tel.: +34-981-167-000; fax: +34-981-138-714. E-mail address: margot{at}udc.es


  Abstract

Background and aim: Cardiac ankyrin repeat protein (CARP), whose expression is down-regulated in response to doxorubicin (Dox) in vitro, has been proposed to be a marker of experimentally-induced cardiac hypertrophy in rodent models. In piglets, the rapid hypertrophy rate of the left ventricle (LV) as compared to that of the right ventricle (RV) represents a natural model of asymmetric ventricular enlargement. We tested whether CARP expression correlates with postnatal ventricular hypertrophy and to what extent CARP can be sensitive to Dox treatment in vivo.

Methods: CARP mRNA and protein levels were quantified (by Northern blot hybridization, semi-quantitative RT-PCR and Western blot) in the piglet heart, both during early postnatal development and upon Dox-induced cardiomyopathy (Dox-CM).

Results: The study revealed: (1) significantly augmented CARP mRNA and protein levels in the LV compared to the RV resulting in left vs. right asymmetry in ventricular CARP expression throughout early postnatal development; (2) dose- and chamber-dependent CARP mRNA and protein enrichment in ventricular myocardium in response to Dox; and (3) abolishment of asymmetric patterns of ventricular CARP expression at heart failure resulting from Dox-CM.

Conclusions: (1) CARP is differentially regulated in the LV and RV during both postnatal development and disease; and (2) monitoring of ventricular CARP expression patterns can be used for further analysis of transition from compensated to overt heart failure.

Key Words: Cardiac left–right asymmetry • Gene expression • CARP • Heart failure • Cardiomyopathy • Doxorubicin

Received May 15, 2003; Revised July 15, 2003; Accepted November 12, 2003

{star} For detailed access on porcine CARP domain structure, CARP dimer formation, design of the Dox treatment protocol, and cardiac parameters of control and Dox-treated piglets see the online-only Figure Supplement Data (Fig. 6, 7 and 8) at http://www.elsevier.com/locate/ejheart.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
L. Duboscq-Bidot, P. Charron, V. Ruppert, L. Fauchier, A. Richter, L. Tavazzi, E. Arbustini, T. Wichter, B. Maisch, M. Komajda, et al.
Mutations in the ANKRD1 gene encoding CARP are responsible for human dilated cardiomyopathy
Eur. Heart J., September 1, 2009; 30(17): 2128 - 2136.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. Moulik, M. Vatta, S. H. Witt, A. M. Arola, R. T. Murphy, W. J. McKenna, A. M. Boriek, K. Oka, S. Labeit, N. E. Bowles, et al.
ANKRD1, the gene encoding cardiac ankyrin repeat protein, is a novel dilated cardiomyopathy gene.
J. Am. Coll. Cardiol., July 21, 2009; 54(4): 325 - 333.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
T. Arimura, J. M. Bos, A. Sato, T. Kubo, H. Okamoto, H. Nishi, H. Harada, Y. Koga, M. Moulik, Y. L. Doi, et al.
Cardiac ankyrin repeat protein gene (ANKRD1) mutations in hypertrophic cardiomyopathy.
J. Am. Coll. Cardiol., July 21, 2009; 54(4): 334 - 342.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Zhang, H. El-Sikhry, K. R. Chaudhary, S. N. Batchu, A. Shayeganpour, T. O. Jukar, J. A. Bradbury, J. P. Graves, L. M. DeGraff, P. Myers, et al.
Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity
Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H37 - H46.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
Y.-J. Wei, C.-J. Cui, Y.-X. Huang, X.-L. Zhang, H. Zhang, and S.-S. Hu
Upregulated expression of cardiac ankyrin repeat protein in human failing hearts due to arrhythmogenic right ventricular cardiomyopathy
Eur J Heart Fail, June 1, 2009; 11(6): 559 - 566.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. L. Scurr, A. D. Guminski, Y.-E. Chiew, R. L. Balleine, R. Sharma, Y. Lei, K. Pryor, G. V. Wain, A. Brand, K. Byth, et al.
Ankyrin Repeat Domain 1, ANKRD1, a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian Cancer
Clin. Cancer Res., November 1, 2008; 14(21): 6924 - 6932.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.